FDA approves Lilly's Olumiant for RA

FDA approved Olumiant baricitinib from Eli Lilly and Co. (NYSE:LLY) and partner Incyte Corp. (NASDAQ:INCY) to treat moderate to severe rheumatoid arthritis in patients who have

Read the full 264 word article

User Sign In